Aldosterone Blockade Attenuates Urinary Monocyte Chemoattractant Protein-1 and Oxidative Stress in Patients with Type 2 Diabetes Complicated by Diabetic Nephropathy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Context: Aldosterone causes organic impairment by enhancement of oxidative stress and subsequent induction of proinflammatory cytokines and chemokines. Objective: This study was designed to investigate the effect of spironolactone, an aldosterone blocker, on oxidative stress and the level of urinary monocyte chemoattractant protein (MCP)-1, a cysteine-cysteine chemokine that may contribute to progression of various nephropathies in type 2 diabetic patients with diabetic nephropathy. Design, Setting, Patients and Other Participants, and Intervention: The patients were randomly assigned to two groups in which they received either spironolactone (50 mg/d; n = 23) or amlodipine (2.5 mg/d; n = 14). Main Outcome Measures: Urinary 8-iso-prostaglandin (PG) F2α (a marker of oxidative stress), urinary MCP-1, and urinary albumin excretion (UAE) were measured at the start of administration (0 months) and after 3 months in each group. Baseline levels of these variables were also measured in 25 age-matched healthy subjects. Results: There were significant positive correlations between log10-transformed (log) 8-iso-PGF2α and log MCP-1 levels in control and diabetic subjects and all subjects combined, but no correlations between log UAE and log 8-iso-PGF2α or log MCP-1 were found in any group. Significant decreases in 8-iso-PGF2α, MCP-1, and UAE were observed with spironolactone (P = 0.0001, P = 0.0041, and P = 0.0037, respectively), and systolic blood pressure significantly decreased after both spironolactone and amlodipine therapy (P = 0.00011 and P = 0.0051, respectively). Conclusions: Our data suggest that urinary MCP-1 is correlated with oxidative stress as measured by urinary 8-iso-PGF2α and that spironolactone can decrease urinary MCP-1 and oxidative stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease
Patrono, C., & FitzGerald, G. A. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2309 · Cited by 453
Cited by
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
The Role of Inflammatory Cytokines in Diabetic Nephropathy
Navarro-González, J. F., & Mora-Fernández, C. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091048 · Cited by 932
MCP-1: Function, regulation, and involvement in disease
Singh, S., Anshita, D., & Ravichandiran, V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107598 · Cited by 883
Tesch, G. H. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00016.2008 · Cited by 417
Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes
Panee, J. (2012) · Cytokine · doi:10.1016/j.cyto.2012.06.018 · Cited by 402
Biomarkers in chronic kidney disease, from kidney function to kidney damage
Lopez-Giacoman, S. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.57 · Cited by 392
Biomarkers of renal function, which and when?
Wasung, M. E., Chawla, L. S., & Madero, M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.039 · Cited by 374
Oxidative stress in early diabetic nephropathy: fueling the fire
Singh, D. K., Winocour, P., & Farrington, K. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.212 · Cited by 353
Guo, C., Ricchiuti, V., Lian, B. Q., Yao, T. M., Coutinho, P., Romero, J. R., Li, J., Williams, G. H., & Adler, G. K. (2008) · Circulation · doi:10.1161/circulationaha.107.748640 · Cited by 342
Biomarkers of Acute and Chronic Kidney Disease
Zhang, W. R., & Parikh, C. R. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114605 · Cited by 332
Inflammatory Cytokines in Diabetic Nephropathy
Donate-Correa, J., Martín-Núñez, E., Muros-de-Fuentes, M., Mora-Fernández, C., & Navarro-González, J. F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/948417 · Cited by 277
Oxidants in Chronic Kidney Disease
Shah, S. V., Baliga, R., Rajapurkar, M., & Fonseca, V. A. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050500 · Cited by 276
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera-Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 261
Aldosterone and Vascular Inflammation
Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.095489 · Cited by 256
Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0030 · Cited by 182
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
Acute hyperglycemia and oxidative stress: Direct cause and effect?
Choi, S.-W., Benzie, I. F. F., Ma, S.-W., Strain, J. J., & Hannigan, B. M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.12.005 · Cited by 149
Metadata
- Authors
- Takebayashi, K., Matsumoto, S., Aso, Y., & Inukai, T.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-06-01
- Volume
- 91
- Issue
- 6
- Pages
- 2214-2217
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1965883240
- Cited by
- 110
- References
- 1
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.